English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Voriconazole (VRC) plasma trough concentrations (C min ) are highly variable, and this could affect treatment efficacy and safety in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). We aimed to describe the intra- and interindividual variation of VRCC min throughout the course of VRC therapy and to identify the determinants of this variation. Clinical data, medications, and VRCC min (n = 308) of 33 AHSCT patients were retrospectively collected. Cytochrome P450 (CYP450) genotypes of CYP2C19, CYP3A4, and CYP3A5 patients were retrospectively determined before allografting, and a combined genetic score was calculated for each patient. The higher the genetic score, the faster the metabolism of the patient. The VRCC min inter- and intraindividual coefficients of variation were 84% and 68%, respectively. The VRC dose (D ) was correlated to VRCC min (r = 0.412,P &lt; 0.0001) only for oral administration. The administration route and the genetic score significantly affected the initial VRCC min . Considering oral therapy, patients with a genetic score of &lt;2 had higher initial VRCC min /D than patients with a genetic score of &gt;2 (P = 0.009). Subsequent VRCC min remained influenced by the genetic score (P = 0.004) but were also affected by pump proton inhibitor comedication (P &lt; 0.0001). The high variability of VRCC min in AHSCT patients is partially explained by the route of administration, treatment with pump proton inhibitors, and the combined genetic score. This study suggests the interest in combined genetic score determination to individualizea priori the VRC dose and underlines the need for longitudinal therapeutic drug monitoring to adapt subsequent doses to maintain the VRCC min within the therapeutic range.

antimicrobial agents and chemotherapy

Variability of Voriconazole Plasma Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Cytochrome P450 Polymorphisms and Comedications on Initial and Subsequent Trough Levels